Bo Cumbo, president and CEO of Solid, commented: “The positive initial three patient, 90-day data in the INSPIRE DUCHENNE trial of SGT-003, our next-generation, investigational gene therapy to treat Duchenne muscular dystrophy, were a milestone in the development of a meaningful treatment candidate for this terrible disease. With the initial data demonstrating robust microdystrophin expression and improvements across biomarkers of muscle integrity and, excitingly, encouraging biomarkers of cardiac and liver health, we continue to dose participants as we prepare to engage with the FDA later this year on the potential for accelerated pathways.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Advances Gene Therapy Pipeline
- Solid Biosciences reports inducement grants under Nasdaq listing rule
- Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board
- Vaccine, gene therapy makers fall after Peter Marks resignation
- Moderna (NASDAQ:MRNA) Leads U.S. Biotechs’ Plunge after FDA’s Top Vaccine Regulator Resigns